P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1851
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Effect of Combined Treatment With Sodium Phenylbutyrate and Cisplatin, Erlotinib, or Gefitinib on Resistant NSCLC Cells

Clinical Pharmacology: Advances and Applications
Pharmacology
2018English

Role of KRAS-LCS6 Polymorphism in Advanced NSCLC Patients Treated With Erlotinib or Docetaxel in Second Line Treatment (TAILOR)

Scientific Reports
Multidisciplinary
2015English

Evaluation of Patient Education System to Improve Their Understanding in Patients Treated With Erlotinib or Gefitinib

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
2015English

P3.13-17 a Retrospective Study: Central Nervous System Response to Osimertinib in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients With Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

Clinical Cancer Research
Cancer ResearchOncology
2007English

Phase II Trials of Erlotinib or Gefitinib in Patients With Recurrent Meningioma

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2009English

Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib

ESMO Open
Cancer ResearchOncology
2016English

Successful Rechallenge With Gefitinib for an Initial Erlotinib-Responder With Advanced Lung Adenocarcinoma

Tuberculosis and Respiratory Diseases
PulmonaryInfectious DiseasesRespiratory Medicine
2011English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy